ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

STX Shield Therapeutics Plc

2.025
0.025 (1.25%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.025 1.25% 2.025 1.95 2.10 2.025 1.975 2.00 632,383 16:11:13
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 4.47M -40.44M -0.0522 -0.39 15.66M

Shield Therapeutics PLC Notice of Results (9623N)

15/08/2017 7:00am

UK Regulatory


Shield Therapeutics (LSE:STX)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Shield Therapeutics Charts.

TIDMSTX

RNS Number : 9623N

Shield Therapeutics PLC

15 August 2017

Shield Therapeutics plc

("Shield" or the "Group")

Notice of Results

London, UK, 15 August 2017: Shield Therapeutics (LSE: STX), a specialty pharmaceutical company focused on secondary care, announces it will report its interim results for the six months ended 30 June 2017 on Wednesday 20 September 2017.

Shield will host a presentation and conference call for analysts at 9.30am BST on the morning of the results in the Guildhall Room at 85 Gresham Street, London, EC2V 7NQ.

- Ends -

For further information please contact:

 
Shield Therapeutics plc                           +44 (0)20 7186 8500 
Carl Sterritt, Chief Executive Officer 
 Joanne Estell, Chief Financial Officer 
 Karl Keegan, Director Corporate Development 
 
  Nominated Adviser and Joint Broker              +44 (0)20 3100 2222 
Liberum Capital Limited 
Christopher Britton 
 Steve Pearce 
 Jonathan Wilkes-Green 
 
 
Joint Broker                           +44 (0)20 7418 8900 
Peel Hunt LLP 
James Steel 
 Alastair Rae 
Oliver Jackson 
 
Financial PR Advisor                  +44 (0) 203 709 5700 
Consilium Strategic Communications 
Mary-Jane Elliott 
 Matthew Neal 
 

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru(R), for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until the mid-2030's. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORBUGDIIXBBGRS

(END) Dow Jones Newswires

August 15, 2017 02:00 ET (06:00 GMT)

1 Year Shield Therapeutics Chart

1 Year Shield Therapeutics Chart

1 Month Shield Therapeutics Chart

1 Month Shield Therapeutics Chart

Your Recent History

Delayed Upgrade Clock